Mostrar el registro sencillo del ítem

Extracellular Vesicle Therapy for Type 1 Diabetes

dc.contributor.authorSoltani, S.
dc.contributor.authorMansouri, K.
dc.contributor.authorEmami Aleagha, M.S.
dc.contributor.authorMoasefi, N.
dc.contributor.authorYavari, N.
dc.contributor.authorShakouri, S.K.
dc.contributor.authorNotararigo, Sara
dc.contributor.authorShojaeian, A.
dc.contributor.authorPociot, F.
dc.contributor.authorYarani, R.
dc.date.accessioned2025-08-26T11:02:34Z
dc.date.available2025-08-26T11:02:34Z
dc.date.issued2022
dc.identifier.citationSoltani S, Mansouri K, Emami Aleagha MS, Moasefi N, Yavari N, Shakouri SK, et al. Extracellular Vesicle Therapy for Type 1 Diabetes. Frontiers in Immunology. 2022;13.
dc.identifier.issn1664-3224
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/6416a4f55db420433b7b6159*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20830
dc.description.abstractType 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing ?-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.en
dc.description.sponsorshipThe Lundbeck foundation grant R303-2018-3148 supported this work.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleExtracellular Vesicle Therapy for Type 1 Diabetes*
dc.typeReviewen
dc.authorsophosSoltani, R. S.
dc.authorsophosMansouri, K.
dc.authorsophosEmami Aleagha, M. S.
dc.authorsophosMoasefi, N.
dc.authorsophosYavari, N.
dc.authorsophosShakouri, S. K.
dc.authorsophosNotararigo, S.
dc.authorsophosShojaeian, A.
dc.authorsophosPociot, F.
dc.authorsophosYarani
dc.identifier.doi10.3389/fimmu.2022.865782
dc.identifier.sophos6416a4f55db420433b7b6159
dc.journal.titleFrontiers in Immunology*
dc.relation.projectIDLundbeck foundation [R303-2018-3148]; Steno Diabetes Center Copenhagen (SDCC) [SDCC 3.D Type1 Biology] Funding Source: researchfish
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.865782/pdf;https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.865782/pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordIDISes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo de Revisiónes
dc.volume.number13


Ficheros en el ítem

Descargar/
Nombre:
942.pdf
Tamaño:
1.292Mb
Formato:
PDF
Descripción:
Soltani S, Mansouri K, Emami Aleagha MS, Moasefi N, Yavari N, Shakouri SK, et al. ...

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional